Idiopathic normal pressure hydrocephalus (iNPH), the leading cause of reversible dementia in older adults, is characterized by urinary incontinence, gait impairment, cognitive decline, and ventriculomegaly. Neuroradiological features rely on visual assessm ...
The amyloid, tau, neurodegeneration (ATN) framework provides a biological staging model of Alzheimer's disease (AD) using magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), or positron emission tomography (PET) biomarkers. MRI, being non-invasive ...
Amyotrophic lateral sclerosis (ALS) with only motor impairment (ALS-pure motor) and the behavioral variant of frontotemporal dementia (bvFTD) are hypothesized to represent extreme ends of a disease spectrum, which encompasses ALS with cognitive/behavioral ...
Alzheimer's disease (AD) can be conceptualized as a network-based syndrome. Network alterations are linked to the molecular hallmarks of AD, involving amyloid-beta and tau accumulation, and consecutively neurodegeneration. By combining molecular and restin ...
Background This study investigated sex differences in the associations between Alzheimer's disease (AD) biomarkers, cognitive performance, and decline in memory clinic settings. Methods 249 participants (females/males:123/126), who underwent tau-PET, amylo ...
Did you know that there are thousands of ways to build a connectome from diffusion MRI tractography, and the choice of approach can hugely impact the final connectome and results? To name only a few: Tractography type: deterministic or probabilistic? Parce ...
Accurate diagnosis of Alzheimer's disease (AD) in Memory Clinics remains challenging due to the limited specificity of conventional clinical assessment and structural imaging. The recent commentary by Vyhnalek and colleagues advocates for the incorporation ...
Introduction: Dementia with Lewy Bodies (DLB) is often associated with Cerebral Amyloid Angiopathy (CAA) based on pathological studies. Current literature in DLB reveals heterogenous findings regarding CAA effects on cognition, but overall suggests a diffu ...
The preclinical phase of Alzheimer’s disease represents a crucial time window for therapeutic intervention but requires the identification of clinically relevant biomarkers that are sensitive to the effects of disease-modifying drugs. Amyloid peptide and t ...
